Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years
NCT01195714
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma
Interventions
DRUG:
Ofatumumab
Sponsor
The Lymphoma Academic Research Organisation